Quale sarebbe il prezzo per Solasia Pharma K.K. (4597)

Il prezzo per Solasia Pharma K.K. (4597) è $0.20877985

Qual è la capitalizzazione di mercato per Solasia Pharma K.K. (4597)

La capitalizzazione di mercato per Solasia Pharma K.K. (4597) è $57.00M

Ricavi di Solasia Pharma K.K. (4597)

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.

Anno	Ricavi	Cambia
Non abbastanza dati per le date fornite.

Anno

Ricavi

Cambia

Non abbastanza dati per le date fornite.

Azienda	Ricavi	Differenza nei ricavi	Il paese
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$6.61B	-	IN

Azienda

Ricavi

Differenza nei ricavi

Il paese